Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

NCT04324164 ·Status: RECRUITING

Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients

NCT03137264 ·Status: COMPLETED

EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC

NCT02988141 ·Status: UNKNOWN

Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

NCT04811001 ·Status: UNKNOWN ·Phase: PHASE2

EGFR Mutation Detection From Advanced NSCLC Patient Tissue and Plasma in EGFR-TKI Treatment

NCT02644889 ·Status: UNKNOWN

K-RAS and EGFR in Lung Cancer

NCT03951233 ·Status: COMPLETED

Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients

NCT04222335 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA

D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer

NCT03861156 ·Status: COMPLETED ·Phase: PHASE2

The Efficacy and Drug Resistance Molecular Biology of Apatinib Combined With EGFR-TK1 Treated for Advanced Slow-progressed Non-Small Cell Lung Cancer (NSCLC)

NCT03811054 ·Status: UNKNOWN ·Phase: PHASE2

Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong

NCT03519958 ·Status: WITHDRAWN

Multicentre Study to Explore the Correlation Between Smoking Pattern and Clinical Efficacy of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Male Patients

NCT00922025 ·Status: COMPLETED

A Retrospective EGFR Mutation Status Study in Chinese NSCLC Patients Using Paired Plasma and Tissue Samples

NCT01382992 ·Status: UNKNOWN

Acquired Resistant Mechanism of the First-generation EGFR TKIs

NCT02804217 ·Status: UNKNOWN

Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas

NCT01380795 ·Status: TERMINATED ·Phase: EARLY_PHASE1

Tyrosine Kinase Inhibitors In Metastatic Non Small Cell Lung Cancer

NCT01163058 ·Status: UNKNOWN

Evaluation of Symptoms Improvement in NSCLC Patients With First-Line Therapy of EGFR Tyrosine Kinase Inhibitor

NCT01947868 ·Status: COMPLETED

A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology

NCT01106781 ·Status: COMPLETED

Observational Study to Characterize the Incidence of EGFR Mutation Positive and Advanced NSCLC Patients

NCT01717105 ·Status: UNKNOWN

Key Performance Indicators for the Assessment of NSCLC Patients Pathway

NCT04676321 ·Status: COMPLETED

Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer

NCT03461185 ·Status: UNKNOWN ·Phase: PHASE2

Treatment Patterns, Outcomes and Testing in EGFRm NSCLC Patients With EGFR TKI 1L Across Europe (REFLECT)

NCT04031898 ·Status: COMPLETED

Retrospective Study in a NSCLC M+ p

NCT01795352 ·Status: COMPLETED

Epidemiological Study to Evaluate the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutation Status in Patients With Newly Diagnosed Locally Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)

NCT01081496 ·Status: COMPLETED

EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC

NCT02886195 ·Status: UNKNOWN ·Phase: PHASE3

Observational Study on the Management of Patients With Non Small Cell Lung Cancer Adenocarcinoma

NCT01167972 ·Status: COMPLETED